Journal:Acta Cryst D:S0907444911047251

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (13:18, 20 June 2022) (edit) (undo)
 
Line 7: Line 7:
<scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/3'>β-Secretase (β-site amyloid precursor protein cleaving enzyme 1; BACE1)</scene> is a transmembrane aspartic protease that cleaves the β-amyloid precursor protein en route to generation of the amyloid β-peptide (Aβ) that is believed to be the principal component of the amyloid plaques seen in the brains of Alzheimer’s disease. It is thus a prime target for the development of inhibitors that may serve as drugs in the treatment and/or prevention of Alzheimer’s disease. The protease domain has a conserved aspartic protease fold, with the <scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/4'>substrate-binding cleft located between the N- and C-terminal lobes</scene> (colored <span style="color:cyan;background-color:black;font-weight:bold;">cyan</span> and <span style="color:yellow;background-color:black;font-weight:bold;">yellow</span>, respectively). <scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/5'>The conserved catalytic Asp dyad, Asp32 and Asp228, is located at the interface of the two lobes.</scene> The hairpin loop in the N-terminal lobe that is known as the <scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/6'>‘flap’ (residues 67-75) partially covers the cleft, and is perpendicular to it</scene>, as is in general the case for the aspartic protease family. Determination of the crystal structures of both apo and complexed BACE1, structural analysis of all crystal structures of BACE1 deposited in the PDB, and MD simulations of <scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/7'>monomeric</scene> and <scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/9'>‘dimeric’</scene> BACE1 were used to study conformational changes in the active-site region of the enzyme (the <font color='magenta'><b>first monomer in magenta</b></font> with a <font color='red'><b>red flap</b></font>, the <span style="color:lime;background-color:black;font-weight:bold;">second one in green</span> with an <span style="color:orange;background-color:black;font-weight:bold;">orange flap</span>). Four new crystal structures were determined: that of a <scene name='Journal:Acta_Cryst_D:1/Cv1/1'>BSIIV/BACE1 complex belonging to space group</scene> P6<sub>1</sub>22 ([[3tpr]], <font color='magenta'><b>BACE1 in magenta</b></font> and <scene name='Journal:Acta_Cryst_D:1/Cv1/2'>BSIIV</scene> in <span style="color:cyan;background-color:black;font-weight:bold;">cyan</span>), those of a <scene name='Journal:Acta_Cryst_D:1/Cv1/3'>second BSIIV/BACE1 complex</scene> ([[3tpp]], <font color='indigo'><b>BACE1 in indigo</b></font> and <scene name='Journal:Acta_Cryst_D:1/Cv1/4'>BSIIV</scene> in <span style="color:lime;background-color:black;font-weight:bold;">green</span>) and of an <scene name='Journal:Acta_Cryst_D:1/Cv1/5'>apo structure</scene> ([[3tpj]], in <span style="color:orange;background-color:black;font-weight:bold;">orange</span>), both belonging to space group C222<sub>1</sub>, and that of a <scene name='Journal:Acta_Cryst_D:1/Cv1/6'>second apo structure belonging to space group C2</scene> ([[3tpl]], in <font color='blueviolet'><b>blueviolet</b></font>). <scene name='Journal:Acta_Cryst_D:1/Cv1/1'>The crystals of the BSIIV complex belonging to space group</scene> P6<sub>1</sub>22 ([[3tpr]], <span style="color:cyan;background-color:black;font-weight:bold;">BSIIV</span>/<font color='magenta'><b>BACE1</b></font>) were obtained by <scene name='Journal:Acta_Cryst_D:1/Cv2/6'>soaking the inhibitor BSIIV into a crystal of the apo enzyme belonging to the same space group</scene>, while those of the complex belonging to space group C222<sub>1</sub> were obtained by <scene name='Journal:Acta_Cryst_D:1/Cv2/7'>cocrystallization of the inhibitor and the enzyme</scene> ([[3tpp]], <span style="color:lime;background-color:black;font-weight:bold;">BSIIV</span>/<font color='indigo'><b>BACE1</b></font>). The two apo structures belonging to different space groups were obtained by cocrystallization in the presence of another low affinity inhibitor, using two different precipitants; in both cases the inhibitor was not seen in the crystals thus obtained. It was found that the <scene name='Journal:Acta_Cryst_D:1/Cv2/8'>conformations of the enzyme in the two BSIIV/BACE1 crystal structures differ significantly from each other</scene>, as do the <scene name='Journal:Acta_Cryst_D:1/Cv1/8'>two apo structures</scene>, particularly in the <scene name='Journal:Acta_Cryst_D:1/Cv2/11'>active-site flap and in the 10S and 113S loops</scene>. This led to a systematic analysis of all the BACE1 crystal structures deposited in the PDB (both apo structures and complexes), and to perform MD simulations on the apo enzyme, so as to investigate the underlying causes for the various conformations adopted by the flap. In particular, an attempt was made to clarify whether they might be a consequence of crystal packing in different space groups, or might indicate that the active site can assume multiple low-energy conformations. The RMSFs of main-chain atoms, calculated based on all the BACE1 crystal structures deposited in the PDB, show that the <scene name='Journal:Acta_Cryst_D:1/Cv4/1'>flap is the most flexible region of the protein</scene>. The <scene name='Journal:Acta_Cryst_D:1/Cv5/2'>minimal distance between the flap residues and the catalytic residue D228, which provides a measure of the extent of opening of the flap</scene>, reveals that the <scene name='Journal:Acta_Cryst_D:1/Cv5/3'>flap adopts an open conformation in all the apo structures</scene> (''e.g.'' [[1w50]], <font color='deepskyblue'><b>colored deepskyblue</b></font>) with two exceptions; not surprisingly, the situation with respect to the structures of the complexes is more complex. <scene name='Journal:Acta_Cryst_D:1/Cv5/4'>In most of the complexes, direct H-bond interaction between main chain atoms of flap residues and the bound inhibitor lock the flap in the closed conformation</scene> (''e.g.'' [[3tpp]], <span style="color:lime;background-color:black;font-weight:bold;">BSIIV</span>/<font color='indigo'><b>BACE1</b></font>), except in a few cases in which the position and orientation of the inhibitors sterically preclude its closing. It is of interest that <scene name='Journal:Acta_Cryst_D:1/Cv5/6'>no direct H-bonds are formed between the inhibitor and the flap in complexes in which the flap is in a more open conformation, as is the case in the crystal structure of the complex obtained by soaking BSIIV into apo crystals of BACE1</scene> ([[3tpr]], <span style="color:cyan;background-color:black;font-weight:bold;">BSIIV</span>/<font color='magenta'><b>BACE1</b></font>); but a direct H-bond between Q73 and BSIIV locks the flap in a closed conformation in the co-crystallized structure ([[3tpp]], <span style="color:lime;background-color:black;font-weight:bold;">BSIIV</span>/<font color='indigo'><b>BACE1</b></font>). It may thus be concluded that formation of a direct H-bond between a main-chain atom of a flap residue and the bound inhibitor is a prerequisite for the flap to assume a closed conformation in a complex. <scene name='Journal:Acta_Cryst_D:1/Cv5/2'>So, there are three possible conformations of flap - locked, open and intermediate.</scene> Interestingly, <scene name='Journal:Acta_Cryst_D:1/Cv6/4'>in all the crystal structures of complexes that belong to space group</scene> P6<sub>1</sub>22 except one, the flap is in an open conformation. Our soaked crystals of the BSIIV/BACE1 complex also belong to space group P6<sub>1</sub>22. Analysis of the crystal packing pattern reveals that in this space group the flap is at a packing interface. MD simulations were carried out to check if the observed packing would influence the conformation of the flap. In the starting model for MD that includes a symmetry-related copy of BACE1, both the degree of opening and the time that the flap dwells in the open state are much larger than in the trajectories generated for the monomer. Thus, the packing pattern in crystals belonging to space group P6<sub>1</sub>22 hinders the conformational change in the flap, which may be the main reason why in our <span style="color:cyan;background-color:black;font-weight:bold;">BSIIV</span>/<font color='magenta'><b>BACE1</b></font> complex ([[3tpr]]) belonging to space group P6<sub>1</sub>22 the <scene name='Journal:Acta_Cryst_D:1/Cv5/6'>bound BSIIV does not cause the flap to adopt a closed conformation, whereas it does so in the complex belonging to space group</scene> C222<sub>1</sub> ([[3tpp]], <span style="color:lime;background-color:black;font-weight:bold;">BSIIV</span>/<font color='indigo'><b>BACE1</b></font>). Thus a systematic study of the conformational flexibility of BACE1 may not only contribute to structure-based drug design of BACE1 inhibitors, but also produce a better understanding of the mechanistic events associated with binding of substrates and inhibitors to the enzyme.
<scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/3'>β-Secretase (β-site amyloid precursor protein cleaving enzyme 1; BACE1)</scene> is a transmembrane aspartic protease that cleaves the β-amyloid precursor protein en route to generation of the amyloid β-peptide (Aβ) that is believed to be the principal component of the amyloid plaques seen in the brains of Alzheimer’s disease. It is thus a prime target for the development of inhibitors that may serve as drugs in the treatment and/or prevention of Alzheimer’s disease. The protease domain has a conserved aspartic protease fold, with the <scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/4'>substrate-binding cleft located between the N- and C-terminal lobes</scene> (colored <span style="color:cyan;background-color:black;font-weight:bold;">cyan</span> and <span style="color:yellow;background-color:black;font-weight:bold;">yellow</span>, respectively). <scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/5'>The conserved catalytic Asp dyad, Asp32 and Asp228, is located at the interface of the two lobes.</scene> The hairpin loop in the N-terminal lobe that is known as the <scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/6'>‘flap’ (residues 67-75) partially covers the cleft, and is perpendicular to it</scene>, as is in general the case for the aspartic protease family. Determination of the crystal structures of both apo and complexed BACE1, structural analysis of all crystal structures of BACE1 deposited in the PDB, and MD simulations of <scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/7'>monomeric</scene> and <scene name='Journal:Acta_Crystallogr_D_Biol_Crystallogr:1/Cv/9'>‘dimeric’</scene> BACE1 were used to study conformational changes in the active-site region of the enzyme (the <font color='magenta'><b>first monomer in magenta</b></font> with a <font color='red'><b>red flap</b></font>, the <span style="color:lime;background-color:black;font-weight:bold;">second one in green</span> with an <span style="color:orange;background-color:black;font-weight:bold;">orange flap</span>). Four new crystal structures were determined: that of a <scene name='Journal:Acta_Cryst_D:1/Cv1/1'>BSIIV/BACE1 complex belonging to space group</scene> P6<sub>1</sub>22 ([[3tpr]], <font color='magenta'><b>BACE1 in magenta</b></font> and <scene name='Journal:Acta_Cryst_D:1/Cv1/2'>BSIIV</scene> in <span style="color:cyan;background-color:black;font-weight:bold;">cyan</span>), those of a <scene name='Journal:Acta_Cryst_D:1/Cv1/3'>second BSIIV/BACE1 complex</scene> ([[3tpp]], <font color='indigo'><b>BACE1 in indigo</b></font> and <scene name='Journal:Acta_Cryst_D:1/Cv1/4'>BSIIV</scene> in <span style="color:lime;background-color:black;font-weight:bold;">green</span>) and of an <scene name='Journal:Acta_Cryst_D:1/Cv1/5'>apo structure</scene> ([[3tpj]], in <span style="color:orange;background-color:black;font-weight:bold;">orange</span>), both belonging to space group C222<sub>1</sub>, and that of a <scene name='Journal:Acta_Cryst_D:1/Cv1/6'>second apo structure belonging to space group C2</scene> ([[3tpl]], in <font color='blueviolet'><b>blueviolet</b></font>). <scene name='Journal:Acta_Cryst_D:1/Cv1/1'>The crystals of the BSIIV complex belonging to space group</scene> P6<sub>1</sub>22 ([[3tpr]], <span style="color:cyan;background-color:black;font-weight:bold;">BSIIV</span>/<font color='magenta'><b>BACE1</b></font>) were obtained by <scene name='Journal:Acta_Cryst_D:1/Cv2/6'>soaking the inhibitor BSIIV into a crystal of the apo enzyme belonging to the same space group</scene>, while those of the complex belonging to space group C222<sub>1</sub> were obtained by <scene name='Journal:Acta_Cryst_D:1/Cv2/7'>cocrystallization of the inhibitor and the enzyme</scene> ([[3tpp]], <span style="color:lime;background-color:black;font-weight:bold;">BSIIV</span>/<font color='indigo'><b>BACE1</b></font>). The two apo structures belonging to different space groups were obtained by cocrystallization in the presence of another low affinity inhibitor, using two different precipitants; in both cases the inhibitor was not seen in the crystals thus obtained. It was found that the <scene name='Journal:Acta_Cryst_D:1/Cv2/8'>conformations of the enzyme in the two BSIIV/BACE1 crystal structures differ significantly from each other</scene>, as do the <scene name='Journal:Acta_Cryst_D:1/Cv1/8'>two apo structures</scene>, particularly in the <scene name='Journal:Acta_Cryst_D:1/Cv2/11'>active-site flap and in the 10S and 113S loops</scene>. This led to a systematic analysis of all the BACE1 crystal structures deposited in the PDB (both apo structures and complexes), and to perform MD simulations on the apo enzyme, so as to investigate the underlying causes for the various conformations adopted by the flap. In particular, an attempt was made to clarify whether they might be a consequence of crystal packing in different space groups, or might indicate that the active site can assume multiple low-energy conformations. The RMSFs of main-chain atoms, calculated based on all the BACE1 crystal structures deposited in the PDB, show that the <scene name='Journal:Acta_Cryst_D:1/Cv4/1'>flap is the most flexible region of the protein</scene>. The <scene name='Journal:Acta_Cryst_D:1/Cv5/2'>minimal distance between the flap residues and the catalytic residue D228, which provides a measure of the extent of opening of the flap</scene>, reveals that the <scene name='Journal:Acta_Cryst_D:1/Cv5/3'>flap adopts an open conformation in all the apo structures</scene> (''e.g.'' [[1w50]], <font color='deepskyblue'><b>colored deepskyblue</b></font>) with two exceptions; not surprisingly, the situation with respect to the structures of the complexes is more complex. <scene name='Journal:Acta_Cryst_D:1/Cv5/4'>In most of the complexes, direct H-bond interaction between main chain atoms of flap residues and the bound inhibitor lock the flap in the closed conformation</scene> (''e.g.'' [[3tpp]], <span style="color:lime;background-color:black;font-weight:bold;">BSIIV</span>/<font color='indigo'><b>BACE1</b></font>), except in a few cases in which the position and orientation of the inhibitors sterically preclude its closing. It is of interest that <scene name='Journal:Acta_Cryst_D:1/Cv5/6'>no direct H-bonds are formed between the inhibitor and the flap in complexes in which the flap is in a more open conformation, as is the case in the crystal structure of the complex obtained by soaking BSIIV into apo crystals of BACE1</scene> ([[3tpr]], <span style="color:cyan;background-color:black;font-weight:bold;">BSIIV</span>/<font color='magenta'><b>BACE1</b></font>); but a direct H-bond between Q73 and BSIIV locks the flap in a closed conformation in the co-crystallized structure ([[3tpp]], <span style="color:lime;background-color:black;font-weight:bold;">BSIIV</span>/<font color='indigo'><b>BACE1</b></font>). It may thus be concluded that formation of a direct H-bond between a main-chain atom of a flap residue and the bound inhibitor is a prerequisite for the flap to assume a closed conformation in a complex. <scene name='Journal:Acta_Cryst_D:1/Cv5/2'>So, there are three possible conformations of flap - locked, open and intermediate.</scene> Interestingly, <scene name='Journal:Acta_Cryst_D:1/Cv6/4'>in all the crystal structures of complexes that belong to space group</scene> P6<sub>1</sub>22 except one, the flap is in an open conformation. Our soaked crystals of the BSIIV/BACE1 complex also belong to space group P6<sub>1</sub>22. Analysis of the crystal packing pattern reveals that in this space group the flap is at a packing interface. MD simulations were carried out to check if the observed packing would influence the conformation of the flap. In the starting model for MD that includes a symmetry-related copy of BACE1, both the degree of opening and the time that the flap dwells in the open state are much larger than in the trajectories generated for the monomer. Thus, the packing pattern in crystals belonging to space group P6<sub>1</sub>22 hinders the conformational change in the flap, which may be the main reason why in our <span style="color:cyan;background-color:black;font-weight:bold;">BSIIV</span>/<font color='magenta'><b>BACE1</b></font> complex ([[3tpr]]) belonging to space group P6<sub>1</sub>22 the <scene name='Journal:Acta_Cryst_D:1/Cv5/6'>bound BSIIV does not cause the flap to adopt a closed conformation, whereas it does so in the complex belonging to space group</scene> C222<sub>1</sub> ([[3tpp]], <span style="color:lime;background-color:black;font-weight:bold;">BSIIV</span>/<font color='indigo'><b>BACE1</b></font>). Thus a systematic study of the conformational flexibility of BACE1 may not only contribute to structure-based drug design of BACE1 inhibitors, but also produce a better understanding of the mechanistic events associated with binding of substrates and inhibitors to the enzyme.
-
PDB references: BACE1, apo, [[3tpj]]; [[3tpl]]; BSIIV complex, [[3tpp]]; [[3tpr]].
+
'''PDB references:''' BACE1, apo, [[3tpj]]; [[3tpl]]; BSIIV complex, [[3tpp]]; [[3tpr]].
<b>References</b><br>
<b>References</b><br>

Current revision

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Jaime Prilusky

This page complements a publication in scientific journals and is one of the Proteopedia's Interactive 3D Complement pages. For aditional details please see I3DC.
Personal tools